Latest filing published 06 Jan 2022 for InMed Pharmaceuticals Inc., €9,467.
Filing timeline
BuySaleInsider track record
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Shane Aaron Johnson: trading record in brief
This profile gathers the share dealings of Shane Aaron Johnson in InMed Pharmaceuticals Inc., where the filings describe the role as senior executive. The record holds 3 filings, for trades running from 15 November 2021 to 6 January 2022.
Purchases make up the whole of the open-market record (3 purchases, €25k). Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. In 2022 alone, the filings show 1 purchase and no sales.
In size, the median ticket on the buying side is €9,451. None of the 3 purchases we analysed coincided with buying by another insider of the same company within 30 days.
On 6 January 2022 came the latest disclosure, an open-market purchase for €9,467 in InMed Pharmaceuticals Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Shane Aaron Johnson
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 8,500 shares@ US$1.2638.0% of flowCommon StockSEC:0001213900-22-001005:0Canonical exit: 6 Apr 2022 (T+90)
- 8,093 shares@ US$1.326638.0% of flowCommon StockSEC:0001213900-21-068212:0Canonical exit: 30 Mar 2022 (T+90)
- 5,000 shares@ US$1.36924.0% of flowCommon StockSEC:0001213900-21-059271:0Canonical exit: 13 Feb 2022 (T+90)
3 of 3 declarations
